Effect of new coumarin derivatives on the impulsive and compulsive components of gambling addiction in rats

Abstract

BACKGROUND: The search for new neuroactive compounds that selectively affect the mechanisms of emotional reinforcement in gambling addiction is of interest. No previous studies have examined the effects of coumarins on gambling addiction.

AIM: This study aimed to investigate the effect of new coumarin derivatives on the impulsive and compulsive components of gambling addiction in rats.

MATERIALS AND METHODS: The effects of drugs on elements of gambling addiction were assessed in rats in the “marble burying” test and “probability and magnitude of reinforcement” in the three-arm maze, a version of the Iowa test. The effects of the following six coumarin derivatives were assessed: LVM-091, LVM-092, LVM-096, LVM-099, LVM-S144, and IEM-2886.

RESULTS: In the “burrowing balls” test, substances synthesized based on coumarins LVM-092, LVM-099, LVM-S144, and IEM-2886 reduced the level of compulsivity, reducing the number of buried balls compared with the control and diazepam groups (p ≤ 0.05). In the “probability and magnitude of reinforcement” test, after the administration of drugs LVM-091, LVM-099, LVM-S144, and IEM-2886, the level of impulsivity and risk behavior decreased, reducing the number of animals entering the sleeve with the greatest reinforcement and its low probability.

CONCLUSIONS: New coumarin derivatives cause an anticompulsive effect and reduce the impulsivity level in rats, which in the future can be used for treating obsessive–compulsive disorders and addictive conditions, such as Internet addiction and gaming addiction.

Keywords

coumarins / gambling addiction / obsessive-compulsive disorders / impulsivity / neurotropic effect

References

[1] Gros L, Debue N, Lete J, et al. Video game addiction and emotional states: possible confusion between pleasure and happiness? Frontiers in Psychology. 2020;10:2894. DOI: 10.3389/fpsyg.2019.02894

[2] Gros L., Debue N., Lete J., et al. Video game addiction and emotional states: possible confusion between pleasure and happiness? // Frontiers in psychology. 2020. Vol. 10. P. 2894. DOI: 10.3389/fpsyg.2019.02894

[3] Iancu I, Lowengrub K, Dembinsky Y, et al. Pathological gambling: an update on neuropathophysiology and pharmacotherapy. CNS Drugs. 2008;22(2):123–138. DOI: 10.2165/00023210-200822020-00004

[4] Iancu I., Lowengrub K., Dembinsky Y., et al. Pathological gambling: an update on neuropathophysiology and pharmacotherapy // CNS Drugs. 2008. Vol. 22, No. 2. P. 123–138. DOI: 10.2165/00023210-200822020-00004

[5] Shabanov PD, Yakushina ND, Lebedev AA. Pharmacology of peptide mechanisms of gambling behavior in rats. Journal of Addiction Problems. 2020;(4(178)):24–44. DOI: 10.47877/0234-0623_2020_4_24

[6] Шабанов П.Д., Якушина Н.Д., Лебедев А.А. Фармакология пептидных механизмов игрового поведения у крыс // Вопросы наркологии. 2020. № 4(178). С. 24–44. DOI: 10.47877/0234-0623_2020_4_24

[7] Lebedev AA, Karpova IV, Bychkov ER, et al. The ghrelin antagonist [D-Lys3]-GHRP-6 decreases signs of risk behavior in a model of gambling addiction in rats by altering dopamine and serotonin metabolism. Neuroscience and Behavioral Physiology. 2022;52(3): 415–421. DOI 10.1007/s11055-022-01255-x

[8] Lebedev A.A., Karpova I.V., Bychkov E.R., et al. The ghrelin antagonist [D-Lys3]-GHRP-6 decreases signs of risk behavior in a model of gambling addiction in rats by altering dopamine and serotonin metabolism // Neuroscience and Behavioral Physiology. 2022. Vol. 52, No. 3. P. 415–421. DOI 10.1007/s11055-022-01255-x

[9] Lebedev AA, Khokhlov PP, Yakushina ND, et al. Pharmacological and biochemical analysis of participation of the ghrelin peptide system in behavioral manifestations of gambling in rats. Experimental and Clinical Pharmacology. 2019;82(6):16–20.

[10] Лебедев А.А., Хохлов П.П., Якушина Н.Д., и др. Фармакологический и биохимический анализ участия пептидной системы грелина в поведенческих проявлениях игровой зависимости у крыс // Экспериментальная и клиническая фармакология. 2019. Т. 82, № 6. С. 16–20.

[11] Skalicka-Woźniak K, Orhan IE, Cordell GA, et al. Implication of coumarins towards central nervous system disorders. Pharmacol Res. 2016;103:188–203. DOI: 10.1016/j.phrs.2015.11.023

[12] Skalicka-Woźniak K., Orhan I.E., Cordell G.A., et al. Implication of coumarins towards central nervous system disorders // Pharmacol Res. 2016. Vol. 103. P. 188–203. DOI: 10.1016/j.phrs.2015.11.023

[13] Daliev BB, Bychkov ER, Myznikov LV, et al. Anticompulsive effects of novel derivatives of coumarin in rats. Reviews on Clinical Pharmacology and Drug Therapy. 2021;19(3):339–344. DOI: 10.17816/RCF193339-344

[14] Далиев Б.Б., Бычков Е.Р., Мызников Л.В., и др. Антикомпульсивные эффекты новых производных кумарина у крыс // Обзоры по клинической фармакологии и лекарственной терапии. 2021. Т. 19, № 3. С. 339–344. DOI: 10.17816/RCF193339-344

[15] Kashirin AO, Polukeev VA, Pshenichnaya AG, et al. Behavioral effects of new compounds based on coumarin in rats. Reviews on Clinical Pharmacology and Drug Therapy. 2020;18(1):37–42. DOI: 10.17816/RCF18137-42

[16] Каширин А.О., Полукеев В.А., Пшеничная А.Г., и др. Поведенческие эффекты новых соединений на основе кумарина у крыс // Обзоры по клинической фармакологии и лекарственной терапии. 2020. Т. 18, № 1. С. 37–42. DOI: 10.7816/RCF18137-42

[17] Akoudad S, Darweesh SK, Leening MJ, et al. Use of coumarin anticoagulants and cerebral microbleeds in the general population. Stroke. 2014;45(11):3436–3439. DOI: 10.1161/STROKEAHA.114.007112

[18] Akoudad S., Darweesh S.K., Leening M.J., et al. Use of coumarin anticoagulants and cerebral microbleeds in the general population // Stroke. 2014. Vol. 45, No. 11. P. 3436–3439. DOI: 10.1161/STROKEAHA.114.007112

[19] Kirsch G, Abdelwahab AB, Chaimbault P. Natural and synthetic coumarins with effects on inflammation. Molecules. 2016;21(10):1322. DOI: 10.3390/molecules21101322

[20] Kirsch G., Abdelwahab A.B., Chaimbault P. Natural and synthetic coumarins with effects on inflammation // Molecules. 2016. Vol. 21, No. 10. P. 1322. DOI: 10.3390/molecules21101322

[21] Al-Majedy YK, Kadhum AH, Al-Amiery AH, et al. Coumarins: the antimicrobial agents. Syst Rev Pharm. 2017;8(1):62–70. DOI: 10.5530/srp.2017.1.11

[22] Al-Majedy Y.K., Kadhum A.H., Al-Amiery A.H., et al. Coumarins: the antimicrobial agents // Syst Rev Pharm. 2017. Vol. 8, No. 1. P. 62–70. DOI: 10.5530/srp.2017.1.11

[23] Kashirin AO, Krylova IB, Selina EN, et al. Antihypoxic effect of new synthetic derivatives of 7-alkoxycoumarin and 4-aminocoumarin in acute hypobaric hypoxia in rats. Reviews on Clinical Pharmacology and Drug Therapy. 2021;19(4):413–420. DOI: 10.17816/RCF194413-420

[24] Каширин А.О., Крылова И.Б., Селина Е.Н., др. Антигипоксическое действие новых синтетических производных 7-алкоксикумарина и 4-аминокумарина при острой гипобарической гипоксии у крыс // Обзоры по клинической фармакологии и лекарственной терапии. 2021. Т. 19. № 4. C. 413–420. DOI: 10.17816/RCF194413-420

[25] Önder A. Chapter 3 — Anticancer activity of natural coumarins for biological targets. Studies in Natural Products Chemistry. 2020;64:85–109. DOI: 10.1016/B978-0-12-817903-1.00003-6

[26] Önder A. Chapter 3 — Anticancer activity of natural coumarins for biological targets // Studies in Natural Products Chemistry. 2020. Vol. 64. P. 85–109. DOI: 10.1016/B978-0-12-817903-1.00003-6

[27] Yakovleva EE, Myznikov LV, Shabanov PD. Comparison of the anticonvulsant activities of substituted hydroxycoumarins and 4-[(3-nitro-2-oxo-2H-chromen-4-yl)amino]butanoic acid. Khimiko-Farmatsevticheskii Zhurnal. 2020;54(9):22–26. DOI: 10.30906/0023-1134-2020-54-9-22-26

[28] Яковлева Е.Е., Мызников Л.В., Шабанов П.Д. Сравнение противосудорожной активности замещенных оксикумаринов и 4-((3-нитро-2-оксо-2H-хромен-4-ил)амино) бутановой кислоты // Химико-фармацевтический журнал. 2020. Т. 54, № 9. С. 22–26. DOI: 10.30906/0023-1134-2020-54-9-22-26

[29] Abdel-Latif NA. Synthesis and antidepressant activity of some new coumarin derivatives. Scientia Pharmaceutica. 2005;73(4): 193–216. DOI: 10.3797/scipharm.aut-05-15

[30] Abdel-Latif N.A. Synthesis and antidepressant activity of some new coumarin derivatives // Scientia Pharmaceutica. 2005. Vol. 73, No. 4. P. 193–216. DOI: 10.3797/scipharm.aut-05-15

[31] Dixit PV, Sahu R, Mishra DK. Marble-burying behavior test as a murine model of compulsive-like behavior. J Pharmacol Toxicol Methods. 2020;102:106676. DOI: 10.1016/j.vascn.2020.106676

[32] Dixit P.V., Sahu R., Mishra D.K. Marble-burying behavior test as a murine model of compulsive-like behavior // J Pharmacol Toxicol Methods. 2020. Vol. 102. P. 106676. DOI: 10.1016/j.vascn.2020.106676

[33] Witkin JM. Animal models of obsessive-compulsive disorder. Current Protoc Neurosci. 2008;45(1):9.30.1–9.30.9. DOI: 10.1002/0471142301.ns0930s45

[34] Witkin J.M. Animal models of obsessive-compulsive disorder // Current Protoc Neurosci. 2008. Vol. 45, No. 1. P. 9.30.1–9.30.9. DOI: 10.1002/0471142301.ns0930s45

[35] Winstanley CA. Gambling rats: insight into impulsive and addictive behavior. Neuropsychopharmacology. 2011;36(1):359. DOI: 10.1038/npp.2010.136

[36] Winstanley C.A. Gambling rats: insight into impulsive and addictive behavior // Neuropsychopharmacology. 2011. Vol. 36, No. 1. P. 359. DOI: 10.1038/npp.2010.136

[37] Zeeb FD, Robbins TW, Winstanley CA. Serotonergic and dopaminergic modulation of gambling behavior as assessed using a novel rat gambling task. Neuropsychopharmacology. 2009;34(10): 2329–2343. DOI: 10.3797/scipharm.aut-05-15

[38] Zeeb F.D., Robbins T.W., Winstanley C.A. Serotonergic and dopaminergic modulation of gambling behavior as assessed using a novel rat gambling task // Neuropsychopharmacology. 2009. Vol. 34, No. 10. P. 2329–2343. DOI: 10.3797/scipharm.aut-05-15

[39] Carrasco-Carballo A, Mendoza-Lara DF, Rojas-Morales JA, et al. In silico study of coumarins derivatives with potential use in systemic diseases. Biointerface Res Appl Chem. 2022;13(3):240. DOI: 10.33263/BRIAC133.240

[40] Carrasco-Carballo A., Mendoza-Lara D.F., Rojas-Morales J.A., et al. In silico study of coumarins derivatives with potential use in systemic diseases // Biointerface Res Appl Chem. 2022. Vol. 13, No. 3. P. 240. DOI: 10.33263/BRIAC133.240

[41] Grant JE, Chamberlain SR. Gambling disorder and its relationship with substance use disorders: Implications for nosological revisions and treatment. Am J Addict. 2015;24(2):126–131. DOI: 10.1111/ajad.12112

[42] Grant J.E., Chamberlain S.R. Gambling disorder and its relationship with substance use disorders: Implications for nosological revisions and treatment // Am J Addict. 2015. Vol. 24, No. 2. P. 126–131. DOI: 10.1111/ajad.12112

[43] Bechara A, Damasio AR, Damasio H, et al. Insensitivity to future consequences following damage to human prefrontal cortex. Cognition. 1994;50(1–3):7–15. DOI: 10.1016/0010-0277(94)90018-3

[44] Bechara A., Damasio A.R., Damasio H., et al. Insensitivity to future consequences following damage to human prefrontal cortex // Cognition. 1994. Vol. 50, No. 1–3. P. 7–15. DOI: 10.1016/0010-0277(94)90018-3

RIGHTS & PERMISSIONS

ECO-vector